All | IPAH | CTD-PAH# | Other-PAH¶ | p-value | |
Subjects n | 102 | 29 | 57 | 16 | |
Age upon first admission years | 58.7±13.6 | 53.7±13.5 | 63.5±11.9 | 50.6±12.8 | <0.001 |
Female | 86 (84.3) | 27 (93.1) | 51 (89.5) | 8 (50.0) | <0.001 |
Race n (White/AA/Hispanic/others) | 59/39/2/2 | 16/12/0/1 | 36/20/0/1 | 7/7/2/0 | 0.05 |
WHO FC pre-admission n (II/III/IV) | 24/59/19 | 10/15/4 | 12/36/9 | 2/8/6 | 0.002 |
Time since PAH diagnosis to first ICU admission months, median (IQR) | 38.9 (12.4–92.3) | 64.5 (25.9–147.3) | 39.5 (11.8–92.1) | 24.6 (9.7–33.9) | 0.002 |
Haemodynamics at PAH diagnosis | |||||
RAP mmHg | 11±6 | 12±6 | 9±6 | 12±7 | 0.14 |
mPAP mmHg | 45±14 | 54±14 | 39±12 | 50±15 | <0.001 |
PCWP mmHg | 10±4 | 10±3 | 11±4 | 11±4 | 0.97 |
Cardiac output L·min−1 | 4.7±1.9 | 4.6±2.0 | 4.8±1.8 | 4.6±2.1 | 0.85 |
Cardiac index L·min−1·m−2 | 2.19±0.64 | 2.11±0.53 | 2.23±0.69 | 2.12±0.58 | 0.61 |
PVR Wood units, median (IQR) | 7.7 (4.8–11.8) | 10.0 (7.6–14.6) | 6.7 (3.0–9.6) | 9.4 (5.3−14.0) | 0.008 |
Comorbidities | |||||
Coronary artery disease | 10 (9.8) | 4 (13.8) | 4 (7.2) | 2 (13.0) | 0.56 |
Systemic hypertension | 23 (22.6) | 8 (27.6) | 14 (24.6) | 1 (6.3) | 0.22 |
Diabetes mellitus | 14 (13.7) | 9 (31.0) | 3 (5.3) | 2 (12.5) | 0.005 |
Peripheral vascular disease | 3 (2.9) | 0 (0) | 2 (3.5) | 1 (6.3) | 0.45 |
Cerebrovascular disease | 3 (2.9) | 0 (0) | 2 (3.5) | 1 (6.3) | 0.45 |
History of depression | 9 (8.8) | 1 (3.5) | 5 (8.8) | 3 (18.8) | 0.68 |
Charlson comorbidity index | |||||
0 | 9 (8.8) | 8 (27.6) | 0 (0) | 1 (6.3) | <0.001 |
1 | 10 (9.8) | 4 (13.8) | 6 (10.4) | 0 (0) | |
2 | 15 (14.7) | 6 (20.7) | 7 (12.3) | 2 (12.5) | |
≥3 | 68 (66.7) | 11 (37.9) | 44 (77.2) | 13 (81.2) |
Data are expressed as mean±sd and n (%) unless otherwise indicated. PAH: pulmonary arterial hypertension; ICU: intensive care unit; IPAH: idiopathic PAH; CTD-PAH: connective tissue diseases PAH; AA: African American; WHO FC: World Health Organization functional class; IQR: interquartile range; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance. #: CTD-PAH includes: 46 scleroderma-associated PAH (SSc-PAH) patients and 11 patients with other CTD-associated PAH conditions; ¶: other-PAH includes: CHD-PAH (3), portopulmonary hypertension-PAH (6) and HIV-associated PAH (7) patients.